Probiotec Limited (ASX: $PBP) has released its half-year report for the period ending 31 December 2023. The report reveals a net operating profit after tax of $3.1 million, with an interim dividend of 3.5 cents per ordinary share declared by the directors.
The Group's underlying net operating profit after tax from continuing activities for the half year was $6.0 million, up from $5.9 million in the prior corresponding period. The Chairman, Jonathan Wenig, expressed satisfaction with the results, highlighting the Group's resilience and steady performance despite the ongoing challenges in the pharmaceutical and consumer health products market.
Probiotec's half-year report demonstrates a solid financial performance, with a focus on maintaining profitability and delivering value to shareholders. The declaration of a 3.5 cents interim dividend reflects the company's commitment to rewarding its shareholders. Looking ahead, Probiotec aims to continue its growth trajectory by leveraging its manufacturing facilities and expanding its distribution network both domestically and internationally. The company remains optimistic about its position in the market and is dedicated to sustaining its operational excellence.